MCID: CLL003
MIFTS: 53

Cellulitis

Categories: Immune diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cellulitis

MalaCards integrated aliases for Cellulitis:

Name: Cellulitis 11 53 41 43 14 16 71 75 31

Classifications:



External Ids:

Disease Ontology 11 DOID:3488
MeSH 43 D002481
SNOMED-CT 68 267833003 74276003
ICD10 31 L03 L03.9
UMLS 71 C0007642 C0007646

Summaries for Cellulitis

MedlinePlus: 41 Cellulitis is an infection of the skin and deep underlying tissues. Group A strep (streptococcal) bacteria are the most common cause. The bacteria enter your body when you get an injury such as a bruise, burn, surgical cut, or wound. Symptoms include: Fever and chills Swollen glands or lymph nodes A rash with painful, red, tender skin. The skin may blister and scab over. Your health care provider may take a sample or culture from your skin or do a blood test to identify the bacteria causing infection. Treatment is with antibiotics. They may be oral in mild cases, or intravenous (by IV) for more severe cases.

MalaCards based summary: Cellulitis is related to orbital cellulitis and erysipelas, and has symptoms including fever, pruritus and exanthema. An important gene associated with Cellulitis is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are ERK Signaling and Innate Immune System. The drugs Cephalexin and Phenoxymethylpenicillin have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and breast, and related phenotypes are digestive/alimentary and cardiovascular system

Disease Ontology: 11 A skin disease where there is a diffuse infection of connective tissue with severe inflammation of dermal and subcutaneous layers of the skin. Cellulitis can be caused by normal skin flora or by exogenous bacteria, and often occurs where the skin has previously been broken: cracks in the skin, cuts, blisters, burns, insect bites, surgical wounds, or sites of intravenous catheter insertion.

Wikipedia: 75 Cellulitis is usually a bacterial infection involving the inner layers of the skin. It specifically... more...

Related Diseases for Cellulitis

Diseases related to Cellulitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1414)
# Related Disease Score Top Affiliating Genes
1 orbital cellulitis 32.9 IL6 CRP CD4
2 erysipelas 31.9 TNF MYOM2 IL6 CRP
3 nocardiosis 31.9 TNF CRP CD4
4 gas gangrene 31.9 TNF IL6 CRP ALB
5 whim syndrome 1 31.7 RAC2 CSF3 CCR6
6 haemophilus influenzae 31.4 TNF LACTB
7 fasciitis 31.3 TNF MYOM2 IL6
8 cavernous sinus thrombosis 31.0 F2 CRP CD4
9 osteomyelitis 31.0 TNF IL6 CSF3 CRP
10 cryptococcosis 31.0 TNF CD4 CCR6
11 panophthalmitis 30.9 CRP CD4
12 hidradenitis 30.9 TNF CRP CAMP
13 lymphadenitis 30.9 TNF IL6 CRP CCR6
14 neutrophilic dermatosis, acute febrile 30.9 TNF CSF3 CRP
15 hidradenitis suppurativa 30.8 TNF CRP CAMP
16 maxillary sinusitis 30.8 RNASE3 LACTB CRP
17 dermatophytosis 30.8 TNF DEFB4A CD4 CCR6 CAMP
18 conjunctivitis 30.8 TNF RNASE3 IL6 IL5
19 thrombophlebitis 30.8 F2 CRP ALB
20 tinea pedis 30.8 DEFB4A CD4 CCR6 CAMP
21 intracranial abscess 30.7 LACTB CRP CD4
22 lymphangitis 30.7 FLT4 CRP CD4 ALB
23 acne 30.7 TNF IL6 DEFB4A CRP
24 endophthalmitis 30.6 TNF IL6 CRP CD4 ALB
25 pyomyositis 30.6 MYOM2 CRP CD4
26 granulomatous dermatitis 30.6 TNF CRP CD4
27 panniculitis 30.6 CSF3 CRP CD4 CCR6
28 erythema nodosum 30.6 TNF IL6 CRP
29 necrotizing fasciitis 30.6 TNF MYOM2 IL6 F2 CRP CAMP
30 liver cirrhosis 30.6 TNF IL6 F2 CHI3L1 ALB
31 dermatitis 30.5 TNF RNASE3 IL6 IL5 IGES CHI3L1
32 toxic shock syndrome 30.5 TNF MYOM2 IL6 IL1R1 CSF3 CRP
33 subdural empyema 30.5 F2 CRP
34 keratitis, hereditary 30.5 TNF IL6 CD4 CCR6
35 lemierre's syndrome 30.5 F2 CRP
36 pleural empyema 30.5 IL6 F2 CRP CD4 ALB
37 purpura 30.5 TNF IL6 F2 CRP
38 angina pectoris 30.5 TNF IL6 CRP
39 scleritis 30.5 TNF IL5 CRP CCR6
40 posterior scleritis 30.4 TNF CRP
41 neutrophilia, hereditary 30.4 IL6 CSF3 CRP
42 folliculitis 30.4 TNF IL5 DEFB4A CD4 CCR6
43 pyoderma gangrenosum 30.4 TNF IL1R1 CSF3 CHI3L1 CCR6
44 vascular disease 30.4 TNF IL6 F2 CRP ALB
45 acquired immunodeficiency syndrome 30.3 TNF IL6 CRP CD4 ALB
46 pulmonary embolism 30.3 F2 CRP ANGPT2 ALB
47 peripheral vascular disease 30.3 TNF IL6 F2 CRP ALB
48 pericarditis 30.3 TNF IL6 CRP
49 otitis externa 30.3 IL6 CRP CD4
50 bursitis 30.3 TNF IL6 CRP

Graphical network of the top 20 diseases related to Cellulitis:



Diseases related to Cellulitis

Symptoms & Phenotypes for Cellulitis

UMLS symptoms related to Cellulitis:


fever; pruritus; exanthema

MGI Mouse Phenotypes related to Cellulitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.91 ALB ANGPT2 CD4 F2 FLT4 IL1R1
2 cardiovascular system MP:0005385 9.9 ALB ANGPT2 CCR6 CRP F2 FLT4
3 immune system MP:0005387 9.86 ALB ANGPT2 CAMP CCR6 CD4 CHI3L1
4 hematopoietic system MP:0005397 9.44 ANGPT2 CAMP CCR6 CD4 CHI3L1 CSF3

Drugs & Therapeutics for Cellulitis

Drugs for Cellulitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
2
Phenoxymethylpenicillin Approved, Vet_approved Phase 4 87-08-1 6869
3
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3 72562361
4
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 10909430
5
Retapamulin Approved Phase 4 224452-66-8 6918462
6
Copper Approved, Investigational Phase 4 7440-50-8 27099
7
Cantharidin Approved, Investigational Phase 4 56-25-7 2545
8
Flucloxacillin Approved, Investigational Phase 4 5250-39-5, 34214-51-2 21319
9
Meticillin Approved, Investigational Phase 4 61-32-5 6087
10
Vancomycin Approved Phase 4 1404-90-6 14969
11
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
12
Dalbavancin Approved, Investigational Phase 4 171500-79-1 16134627
13 beta-Lactams Phase 4
14 Lactams Phase 4
15 Penicillins Phase 4
16 Anti-Infective Agents, Local Phase 4
17 Copper Supplement Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Anti-Bacterial Agents Phase 4
20 Anti-Infective Agents Phase 4
21
Probenecid Approved, Investigational Phase 3 57-66-9 4911
22
Moxifloxacin Approved, Investigational Phase 3 186826-86-8, 354812-41-2, 151096-09-2 152946
23
Oritavancin Approved, Investigational Phase 3 171099-57-3 16136912
24
Telavancin Approved Phase 3 372151-71-8 21014972 3081362
25
Caffeine Approved Phase 2, Phase 3 58-08-2 2519
26
Mupirocin Approved, Investigational, Vet_approved Phase 3 12650-69-0 446596
27
Ciprofloxacin Approved, Investigational Phase 2, Phase 3 85721-33-1, 93107-08-5 2764
28
Levofloxacin Approved, Investigational Phase 2, Phase 3 100986-85-4 149096
29
Ofloxacin Approved Phase 2, Phase 3 82419-36-1 4583
30
Imipenem Approved Phase 3 74431-23-5, 64221-86-9 104838
31
Meropenem Approved, Investigational Phase 3 119478-56-7, 96036-03-2 441130
32
Cilastatin Approved, Investigational Phase 3 82009-34-5 6435415
33
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 3 439-14-5 3016
34
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 3 55-56-1 2713 9552079
35
Ethanol Approved Phase 3 64-17-5 702
36
Fusidic acid Approved, Investigational Phase 3 6990-06-3 3000226
37
Ceftobiprole medocaril Approved, Experimental, Investigational Phase 3 376653-43-9 139292184
38
Ceftobiprole Approved, Investigational Phase 3 209467-52-7 139595999
39
Ceftazidime Approved Phase 3 78439-06-2, 72558-82-8 5481173
40
Clindamycin Approved, Vet_approved Phase 3 18323-44-9, 24729-96-2 29029
41
Metronidazole Approved Phase 3 443-48-1, 69198-10-3 4173
42
Oxacillin Approved, Investigational Phase 3 66-79-5 6196
43
Teicoplanin Approved, Investigational Phase 3 61036-62-2 16170201
44
Cefadroxil Approved, Vet_approved, Withdrawn Phase 3 66592-87-8, 50370-12-2 47965
45
Aztreonam Approved Phase 3 78110-38-0 5742832
46 Norgestimate, ethinyl estradiol drug combination Phase 3
47 Vaccines Phase 3
48 Cephalosporins Phase 3
49 Immunoglobulins Phase 3
50 Antibodies Phase 3

Interventional clinical trials:

(show top 50) (show all 133)
# Name Status NCT ID Phase Drugs
1 Oral Flucloxacillin Alone Versus Flucloxacillin and Phenoxymethylpenicillin for the Emergency Department Outpatient Treatment of Cellulitis: a Non-inferiority Randomised Controlled Trial. Unknown status NCT02922686 Phase 4 Flucloxacillin;Phenoxymethylpenicillin;Placebo (for phenoxymethylpenicillin)
2 Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence Unknown status NCT02566928 Phase 4 2% mupirocin ointment
3 A Double Blind Randomised Control Trial to Measure the Effect of the Addition of Clindamycin to Flucloxacillin for the Treatment of Limb Cellulitis Completed NCT01876628 Phase 4 Flucloxacillin;Clindamycin;Placebo oral capsule
4 Randomised Controlled Trial to Investigate Whether Prophylactic Antibiotics Can Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg (PATCH I) Completed NCT00552799 Phase 4 Penicillin VK
5 Effects of Daptomycin in the Levels of IL-1, IL-6 and TNF in Patients With Complicated Cellulitis/Erisipela in Comparison With Vancomycin or Oxacillin Completed NCT01626560 Phase 4 Daptomycin;Vancomycin
6 High-dose Cephalexin for Cellulitis: A Pilot Randomized Controlled Trial Completed NCT04471246 Phase 4 Cephalexin
7 A Multicenter, Randomized Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in the Treatment of Cellulitis or Erysipelas Completed NCT00295178 Phase 4 Daptomycin;Vancomycin
8 Randomized Clinical Trial of Wound Packing Following Incision and Drainage of Superficial Skin Abscesses in the Pediatric Emergency Department Completed NCT00746109 Phase 4
9 Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections Completed NCT01549613 Phase 4 Daptomycin;Vancomycin
10 Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections Documented or at Risk of Methicillin-Resistant S. Aureus Completed NCT02582203 Phase 4 Ceftaroline;Vancomycin
11 The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown Completed NCT03929224 Phase 4 Medicinal honey;Bacitracin
12 An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months Completed NCT00555061 Phase 4 Retapamulin Ointment, 1%
13 Comparison of Cephalexin Versus Clindamycin in the Empiric, Outpatient Treatment of Suspected Staphylococcal Cutaneous Infections in the Era of Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA) Completed NCT00352612 Phase 4 clindamycin;cephalexin
14 A Randomized Study to Evaluate Comparative Effectiveness, Inpatient Resource Utilization, and Cost of Daptomycin vs. Vancomycin in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Documented Methicillin-resistant Staphylococcus Aureus (MRSA) Completed NCT01419184 Phase 4 Daptomycin;Vancomycin
15 Using a Cold Atmospheric Plasma Device to Treat Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients Recruiting NCT05070754 Phase 4 Canthardin Collodion
16 Duration of Antibiotic Therapy for Cellulitis (DANCE): a Randomized Controlled Trial Comparing 6 to 12 Days of Antibiotic Therapy for Patients Hospitalized With Cellulitis Terminated NCT02032654 Phase 4 Flucloxacillin;Placebo (for flucloxacillin)
17 A Multicentre, Open Label, Uncontrolled Clinical Trial to Evaluate Efficacy and Safety of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections (cSSTI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA) Terminated NCT00463801 Phase 4 Daptomycin
18 Hospital Avoidance Strategies for Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Terminated NCT03372941 Phase 4 Dalbavancin
19 Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department Unknown status NCT00323219 Phase 3 Cefazolin and Moxifloxacin
20 A Pilot Randomized Controlled Trial Assessing the Effectiveness of Alcohol Swabs in Preventing Infections in Pediatric Patients Receiving Vaccinations Unknown status NCT03131843 Phase 3 Alcohol;No alcohol
21 A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed NCT02127970 Phase 3 Dalbavancin;Dalbavancin-matching Placebo
22 Ultrasound Guided Needle Drainage Versus Formal Incision and Drainage of Superficial Soft Tissue Abscesses in the Emergency Department Setting Completed NCT01085929 Phase 3
23 The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy. Completed NCT03556917 Phase 2, Phase 3
24 A Multicenter, Active-Controlled, Randomized Study to Evaluate the Safety and Efficacy of Levofloxacin Versus Ciprofloxacin HCl in the Treatment of Mild to Moderate Skin and Skin Structure Infections in Adults Completed NCT00257036 Phase 2, Phase 3 levofloxacin
25 A Multicenter, Randomized, Double Blind, Comparative Trial of Intravenous MERREM (Meropenem, ICI 194,660) vs PRIMAXIN I.V. (Imipenem-cilastatin) in the Treatment of Hospitalised Subjects With Complicated Skin and Skin Structure Infections. Completed NCT00619710 Phase 3 Meropenem;Imipenem-cilastatin
26 A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II) Completed NCT01252732 Phase 3 Single-Dose IV Oritavancin Diphosphate;IV Vancomycin
27 A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO I) Completed NCT01252719 Phase 3 Single-Dose IV Oritavancin Diphosphate;IV Vancomycin;Placebo
28 A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed NCT01431339 Phase 3 IV Dalbavancin;Vancomycin/Linezolid
29 A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed NCT01339091 Phase 3 Dalbavancin;Vancomycin / Linezolid
30 A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome Completed NCT00465985 Phase 3 ACZ885;Placebo
31 A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus Completed NCT00852540 Phase 3 Retpamulin Ointment, 1%;Linezolid
32 An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Completed NCT00685373 Phase 3 Canakinumab (ACZ885)
33 A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL Completed NCT00684177 Phase 3 Retapamulin Ointment, 1%;Placebo ointment
34 An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo Completed NCT00133874 Phase 3 SB-275833 ointment, 1%
35 A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus Completed NCT00107978 Phase 3 Telavancin;Vancomycin
36 A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections Completed NCT00210899 Phase 3 ceftobiprole medocaril;Vancomycin plus Ceftazidime
37 A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections Completed NCT00228982 Phase 3 Ceftobiprole medocaril;Vancomycin
38 An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan Completed NCT00991146 Phase 3 canakinumab
39 A Phase 3, Randomized, Double Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus Completed NCT00091819 Phase 3 Telavancin;Vancomycin
40 Evaluation of Novel Antimicrobial Hand Towels Completed NCT02512614 Phase 2, Phase 3
41 A 2X2 Phase III Open-label Clinical Trial of Therapy for Patients With Recurrent Methicillin Resistant Staphylococcus Aureus Infections: Topical Nasal & Body Decolonization and/or Environmental Decontamination vs. Standard of Care Completed NCT00560599 Phase 3 mupirocin and chlorhexidine;mupirocin, chlorhexidine, & household cleaning/disinfection
42 An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS) Completed NCT01576367 Phase 3
43 A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS) Completed NCT01302860 Phase 3 ACZ885
44 A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections Recruiting NCT02814916 Phase 3 Dalbavancin single dose;Dalbavancin two dose;Comparator
45 A Blinded, Non-inferiority Phase III Trial of 5 Versus 7 Days of Oral Flucloxacillin in Primary Care Patients With Lower Limb Cellulitis Not yet recruiting NCT05584007 Phase 3 Flucloxacillin Only Product in Oral Dose Form;Placebo Only Product in Oral Dose Form
46 Intravenous Cefazolin Plus Oral Probenecid vs. Oral Cephalexin for the Treatment of Cellulitis: a Randomized Controlled Trial Completed NCT01029782 Phase 2 IV cefazolin plus oral probenecid and placebo cephalexin;Oral cephalexin and saline IV plus probenecid placebo
47 A Randomized, Parallel Group, Controlled Study to Assess the Efficacy and Safety of NMBM in the Treatment of Subjects With a Post-cellulitis and Venous Leg Ulcer Completed NCT01770509 Phase 1, Phase 2
48 Phase 2 Open-Label Safety and Exploratory Skin Lesion Measurement Study of 6-Day Oral TR-701 FA in Skin Abscess and Cellulitis Patients Completed NCT01519778 Phase 2 TR701 FA
49 Nuvocid® (Oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI) Completed NCT00514527 Phase 2 oritavancin
50 A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) Completed NCT00061633 Phase 2 Telavancin;Vancomycin or antistaphylococcal penicillin

Search NIH Clinical Center for Cellulitis

Cochrane evidence based reviews: cellulitis

Genetic Tests for Cellulitis

Anatomical Context for Cellulitis

Organs/tissues related to Cellulitis:

MalaCards : Skin, Lymph Node, Breast, Bone, Eye, Bone Marrow, Spinal Cord

Publications for Cellulitis

Articles related to Cellulitis:

(show top 50) (show all 10109)
# Title Authors PMID Year
1
Compression stockings for recurrent cellulitis. 62 41
35292457 2022
2
Diagnostic accuracy of contrast-enhanced CT for neck abscesses: A systematic review and meta-analysis of positive predictive value. 62 41
36288374 2022
3
Smooth versus Textured Implant Breast Reconstruction: Patient-Reported Outcomes and Complications. 62 41
34705770 2021
4
Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. 53 62
16965327 2006
5
Pelvic cellulitis, a rare complication of bartholinitis: report of two cases. 62
36457796 2023
6
Fulminant endogenous panophthalmitis caused by Clostridium septicum infection. 62
35170633 2023
7
Acute inflammatory presentation of orbital metastasis from urothelial carcinoma: a case report. 62
34078220 2022
8
Orbital abscess: 20 years' experience at a tertiary eye care center. 62
35195044 2022
9
Microbiological profile and antibiotic susceptibility trends in orbital cellulitis in India: an analysis over 15 years. 62
34939530 2022
10
Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001-2019. 62
36418019 2022
11
Machine learning prediction of diabetic foot ulcers in the inpatient population. 62
34461765 2022
12
Paediatric lymphoedema: An audit of patients seen by the paediatric and primary lymphoedema group of vascular European Reference Network (VASCERN). 62
36243335 2022
13
Contrasting presentations of the same disease: A comparison of two cases of amyloidosis presenting with eyelid involvement. 62
36217437 2022
14
Racial and ethnic differences in hospital admissions for cellulitis in the United States: A cross-sectional analysis. 62
36041556 2022
15
Cellulitis due to Pasteurella stomatis and Actinomyces canis following dog bite. 62
36243951 2022
16
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. 62
36402160 2022
17
Effectiveness of postoperative oral administration of cephalexin and metronidazole on surgical site infection among obese women undergoing cesarean section: a randomized, double-blind, placebo-controlled, parallel-group study-phase III. 62
36471429 2022
18
Factors Associated With Gastrostomy Tube Complications in Infants With Congenital Heart Disease. 62
36030602 2022
19
Accuracy of the International Classification of Diseases, 9th Revision for Identifying Infantile Eye Disease. 62
34821545 2022
20
The higher incidence of cases with poor prognostic factors in breast cancer patients who developed both breast cancer-related lymphedema and cellulitis might explain higher mortality. 62
36029290 2022
21
Monkeypox as an emerging infectious disease: the ophthalmic implications. 62
36216412 2022
22
Long-term survival analysis of free flap reconstruction in patients with collagen vascular disorders. 62
36274012 2022
23
International Validation of a Methicillin-Resistant Staphylococcus aureus Risk Assessment Tool for Skin and Soft Tissue Infections. 62
36319943 2022
24
Continuous glucose monitoring in an infant with panhypopituitarism having hypoglycemia on growth hormone therapy. 62
36113970 2022
25
Understanding the Prodromal Period of Necrotizing Soft Tissue Infections of the Genitalia (Fournier's Gangrene) and the Incidence, Duration, and Risk Factors Associated With Potential Missed Opportunities for an Earlier Diagnosis: A Population-based Longitudinal Study. 62
36006046 2022
26
Prophylactic postoperative antibiotics after emergent cesarean delivery and risk of postpartum infection or wound complication. 62
34008468 2022
27
Breast cancer-related lymphedema correlated with incidence of cellulitis and mortality. 62
35960614 2022
28
Ceftazidime encephalopathy developed without the elevation of cerebrospinal fluid concentration of ceftazidime: A case report of two cases. 62
36028210 2022
29
Infectious complications in adult patients with idiopathic minimal change nephrotic syndrome undergoing immunosuppressive therapy. 62
36209374 2022
30
Management patterns and outcomes of patients hospitalized with diabetic foot ulcers at one tertiary care hospital. 62
36474123 2022
31
Liposuction to improve vascular access in hemodialysis patients with arteriovenous fistulas. 62
36425251 2022
32
The arteriovenous fistula and the history of a forgotten pioneer. 62
36325314 2022
33
Omadacycline for a Carbapenem-Resistant Enterobacter cloacae-Associated Wound Infection. 62
36340620 2022
34
Lymphoedema in advanced cancer: does subcutaneous needle drainage improve quality of life? 62
31471494 2022
35
Necrotizing Soft-Tissue Infection of the Trunk Resulting From Wound Caused by a Centipede: A Case Report. 62
36350797 2022
36
Evolving antibiotic resistance in Group B Streptococci causing invasive infant disease: 1970-2021. 62
36352262 2022
37
Institution of same-day total joint replacement at an urban safety net hospital during the COVID-19 pandemic. 62
36060728 2022
38
Characteristics of Venous Leg Ulcer Patients at a Tertiary Wound Care Center. 62
36410701 2022
39
Uptake of breast reconstruction following mastectomy: a Gold Coast experience. 62
35426189 2022
40
Bitten to the Bone: A Case of Anxiety-Induced Osteomyelitis. 62
36408316 2022
41
K-wire Fixation of Closed Hand Fractures Outside the Main Operating Room Does Not Increase Infections. 62
36438460 2022
42
Rate of concomitant cellulitis and osteoarticular infections in a pediatric population. 62
36445357 2022
43
Cervico-thoracic cellulitis at the Yalgado Ouedraogo University Hospital: About 50 cases. 62
35853556 2022
44
Update on orbital vascular anomalies in pediatrics: imaging studies and management. 62
36346341 2022
45
Vascularized Lymph Node Transfer Improved Outcomes of Elderly Patients with Secondary Upper Extremity Lymphedema. 62
35780215 2022
46
Power-assisted Liposuction for Lymphedema: A Cost-utility Analysis. 62
36415620 2022
47
A Single Institution Multi-disciplinary Approach to Power-assisted Liposuction for the Management of Lymphedema. 62
33156069 2022
48
Diagnostic challenge: Diffuse large B-cell lymphoma masquerading as orbital cellulitis. 62
36380613 2022
49
Primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) simulating periorbital cellulitis. 62
36325738 2022
50
Emergent Off-Label TAVR for Native Aortic Valve Endocarditis. 62
36318462 2022

Variations for Cellulitis

Expression for Cellulitis

Search GEO for disease gene expression data for Cellulitis.

Pathways for Cellulitis

Pathways related to Cellulitis according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 ANGPT2 CCR6 CD4 CSF3 FLT4 IL1R1
2
Show member pathways
13.66 TNF RNASE3 RAC2 IL6 IL5 IL1R1
3
Show member pathways
13.52 TNF IL6 IL5 IL1R1 FLT4 F2
4
Show member pathways
13.44 TNF RAC2 IL6 IL5 IL1R1 FLT4
5
Show member pathways
13.17 ANGPT2 CCR6 CD4 CSF3 FLT4 IL1R1
6
Show member pathways
12.72 TNF RAC2 IL6 IL5 IL1R1 FLT4
7
Show member pathways
12.5 TNF IL6 F2 CD4 ANGPT2
8
Show member pathways
12.32 TNF IL6 IL1R1 DEFB4A
9
Show member pathways
12.2 CAMP CCR6 CD4 DEFB4A RNASE3
10 11.83 TNF IL6 IL5 CSF3 CD4
11
Show member pathways
11.68 IL6 CRP CD4
12 11.66 RAC2 IL6 CD4
13 11.65 TNF IL6 CD4
14 11.63 TNF IL6 CRP
15 11.58 TNF IL6 IL5 CSF3
16
Show member pathways
11.54 TNF IL6 IL5
17 11.46 TNF IL5 IL1R1 CD4 CCR6
18 11.44 TNF IL6 DEFB4A CAMP
19 11.38 TNF IL6 IL1R1 CSF3
20 11.25 TNF IL6 IL5
21 11.14 TNF IL6 IL5
22 10.98 TNF IL6 CRP
23 10.9 TNF RAC2 IL6 IL5 FLT4 CSF3
24 10.71 IL6 IL5
25 10.48 TNF IL6 IL5 CSF3 CD4
26
Show member pathways
10.28 TNF IL6

GO Terms for Cellulitis

Cellular components related to Cellulitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.03 TNF RNASE3 IL6 IL5 F2 DEFB4A
2 extracellular region GO:0005576 9.77 ALB ANGPT2 CAMP CHI3L1 CRP CSF3

Biological processes related to Cellulitis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.23 CHI3L1 CRP IL1R1 IL5 IL6 TNF
2 positive regulation of protein phosphorylation GO:0001934 10.13 TNF FLT4 F2 CD4 CAMP
3 positive regulation of DNA-binding transcription factor activity GO:0051091 10.08 TNF IL6 IL5 CSF3
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.01 IL6 IL5 CSF3 CD4
5 acute-phase response GO:0006953 9.97 IL6 F2 CRP
6 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.97 CAMP DEFB4A F2 RNASE3
7 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 9.86 TNF IL6 IL5 F2
8 defense response to Gram-negative bacterium GO:0050829 9.85 CAMP CD4 DEFB4A IL6 RNASE3
9 negative regulation of lipid storage GO:0010888 9.8 TNF IL6 CRP
10 immune response GO:0006955 9.8 TNF IL6 IL5 IL1R1 DEFB4A CSF3
11 defense response to Gram-positive bacterium GO:0050830 9.4 TNF RNASE3 IL6 DEFB4A CRP CAMP

Molecular functions related to Cellulitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 9.1 RNASE3 F2 CAMP

Sources for Cellulitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....